http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104860890-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-10 |
| filingDate | 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104860890-B |
| titleOfInvention | T790M mutant egfs R inhibitor and its application in antineoplastic is prepared |
| abstract | The invention provides T790M mutant egfs R inhibitor and its application in antineoplastic is prepared, the inhibitor is the pyrimidines with logical formula (I) architectural feature.Such compound can suppress kinds of tumor cells, especially can selectively acting in EGFR L858R/T790M and EGFRE745_A750/T790M lung carcinoma cells.Wild type cancer cell is contrasted, the IC50 of such compound wants high 10 times even 100 times of order of magnitude difference.Such compound be it is a kind of novel can overcome existing EGFR TKI drug resistance and selective protease inhibitors, can be applied to prepare antineoplastic. |
| priorityDate | 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 240.